Sign In
Buy GERN
$1.16
-0.0100 (-0.85%)
At Close: Jun 03, 2026
Geron Stock Doubles After Imetelstat Receives FDA Panel Approval
06:10am, Wednesday, 20'th Mar 2024
Geron Inc. NASDAQ: GERN is a clinical-stage biotech in the medical sector focused on developing cell therapies to treat certain types of blood cancers and myeloid hematologic malignancies. Their lead
Geron Corporation Announces Pricing of $150 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
09:07am, Tuesday, 19'th Mar 2024
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the pricing of an underwritten offering consisting of 41,999,99
Choosing the Right Penny Stocks, 3 Hot Tips
05:21am, Monday, 18'th Mar 2024
Navigating the realm of penny stocks can unlock pathways to significant financial growth, presenting a landscape ripe with opportunities for those astute enough to capitalize on them. Central to achie
Can Geron Corporation maintain momentum following FDA's backing?
08:31am, Sunday, 17'th Mar 2024
Friday saw an unprecedented surge in the stock of Geron Corporation (NASDAQ:GERN), with shares ending the day up a staggering 92%. This surge, marking a historic milestone for the company, was ignited
Geron's stock soars 95% after FDA advisory panel votes in favor of blood-disorder drug
11:50am, Friday, 15'th Mar 2024
Geron Corp.'s stock rose 95% Friday, after an advisory panel to the Food and Drug Administration voted 12-to-2 in favor of the company's blood-disorder drug imetelstat and said its benefits outweigh t
Why Is Geron (GERN) Stock Up 94% Today?
10:47am, Friday, 15'th Mar 2024
Geron (NASDAQ: GERN ) stock is rocketing higher on Friday following news that advisors to the Food and Drug Administration (FDA) are backing its blood disorder drug, imetelstat. According to a press r
Geron (GERN) Gets ODAC Votes for Blood Disorder Drug, Shares Up
10:01am, Friday, 15'th Mar 2024
Geron's (GERN) pipeline candidate, imetelstat, gets FDA Committee backing for the treatment of transfusion-dependent (TD) anemia in adult patients with low-to-intermediate-1 risk myelodysplastic syndr
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to t
Geron's blood disorder drug gets FDA advisers' backing
03:28pm, Thursday, 14'th Mar 2024
Advisers to the U.S. Food and Drug Administration on Thursday voted in favor of Geron's blood disorder drug, stating that, based on late-stage trial data, the benefits outweigh treatment associated ri
US FDA staff flags concerns about Geron's anemia treatment
09:44am, Tuesday, 12'th Mar 2024
The U.S. health regulator's staff on Tuesday flagged concerns that the late-stage trial data on Geron's anemia drug does not show whether the risks of treatment with imetelstat are outweighed by the p
Geron Post 2023 Earnings - Gearing Up For Critical Imetelstat AdCom, PDUFA
10:30am, Tuesday, 05'th Mar 2024
Geron Corporation's lead candidate, imetelstat, is awaiting FDA approval for the treatment of transfusion-dependent anemia in adult patients with low-to-intermediate-1 risk myelodysplastic syndromes.
Geron Corporation Reports Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
07:05am, Wednesday, 28'th Feb 2024
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to t
Geron to Announce Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024
04:30pm, Wednesday, 14'th Feb 2024
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that it will release its fourth quarter and full-year 2023 fina
Geron (GERN) Upgraded to Buy: Here's Why
01:32pm, Friday, 15'th Dec 2023
Geron (GERN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Penny Stocks To Buy? 4 To Watch Before Next Week
10:48am, Friday, 15'th Dec 2023
Penny stocks are the jittery nerves of the stock market – even minor news events can make them swing unpredictably. By definition, penny stocks are shares of companies traded below $5 per share and
